Skip to main content

Published locations for Time to disease progression drives outcomes after second-line BTKi therapy in relapsed or refractory MCL

Primary tabs

  • View
  • Get Stamp Tags
  • Published Locations

Breadcrumb

  1. Home
  3. Time to disease progression drives outcomes after second-line BTKi therapy in relapsed or refractory MCL

User login

  • Reset your password
  • /content/time-disease-progression-drives-outcomes-after-second-line-btki-therapy-relapsed-or
  • /b-cell-lymphoma-icymi/article/264258/b-cell-lymphoma/time-disease-progression-drives-outcomes-after